Representative(s):

Amy Plaisance
aplaisance@guardanthealth.com
224-558-7238

 

 

 

 

We are dedicated to helping patients at all stages of cancer live longer and healthier lives through the power of blood tests and the data they unlock— from informing better treatment in patients with advanced cancer, to new ways of monitoring recurrence in cancer survivors, and screening to find cancer at its earliest and most treatable in the general population.

Visit our website to learn more:  https://guardanthealth.com/

 

Our Guardant360® CDx test is FDA-approved for complete genomic testing across all solid cancers, providing doctors guideline-complete genomic results in 7 days from a simple blood draw to inform treatment decisions. A blood test does not require tissue testing, enabling more patients to benefit from the growing number of FDA-approved targeted therapies. Starting with the Guardant360 CDx test for complete genomic profiling identifies more patients with actionable biomarkers more quickly than starting with tissue biopsy.1-3 The test covers all genes recommended by the National Comprehensive Cancer Network, including the 55 most relevant to clinical care. The test is also approved as a companion diagnostic to identify patients with non-small cell lung cancer who may benefit from treatment with TAGRISSO® (osimertinib), RYBREVANT™ (amivantamab-vmjw), and LUMAKRAS™ (sotorasib).

 


Our Guardant Reveal™ test is the first blood-only test that detects residual and recurrent disease in two weeks, without the need for a tissue biopsy. The test detects circulating tumor DNA (ctDNA) in blood after surgery to identify patients with residual disease who may benefit most from adjuvant therapy. Our first indication is early-stage colorectal cancer with additional cancer types to follow.